Navigation Links
Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists
Date:1/21/2008

tin also has been used off-label by retinal specialists and ophthalmologists to treat thousands of patients with age-related macular degeneration (AMD), a disease that causes blindness.

About Wedgewood Pharmacy

A compounding pharmacy creates customized medications for individual patients in response to a licensed practitioner's prescription. Wedgewood Pharmacy is one of the largest compounding pharmacies in the United States, serving more than 20,000 prescribers of compounded medications. It is located in Swedesboro NJ and licensed throughout the United States.

Background: About Compounding Pharmacy

Because every patient is different and has different needs, customized, compounded medications are a vital part of quality medical care. The basis of the profession of pharmacy has always been the "triad," the patient- prescriber-pharmacist relationship. Through this relationship, patient needs are determined by a prescriber, who chooses a treatment regimen that may include a compounded medication. Prescribers often prescribe compounded medications for reasons that include (but are not limited to) the following situations:

-- When needed medications are discontinued by or generally unavailable

from pharmaceutical companies, often because the medications are no

longer profitable to manufacture;

-- When the patient is allergic to certain preservatives, dyes or binders

in available off-the shelf medications;

-- When treatment requires tailored dosage strengths for patients with

unique needs (for example, an infant);

-- When a pharmacist can combine several medications the patient is taking

to increase compliance;

-- When the patient cannot ingest the medication in its commercially

available form and a pharmacist can prepare the medication in cream,

liquid or other form that the patient can easily take; and

-- When medications require flavor
'/>"/>

SOURCE Wedgewood Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
2. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
3. Chambersburg Hospital Streamlines Pharmacy Process and Increases Patient Safety With Omnicell WorkflowRx 5.0
4. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
5. Diplomat Specialty Pharmacy Hires Vice President of Managed Markets
6. Good Neighbor Pharmacy Joins with Diversified Racing Solutions to Enter NASCAR Nationwide Series in 2008
7. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
8. Good Neighbor Pharmacy(R) Ironman Competitor Inspires Individuals with Diabetes to Live Without Limits
9. Baxter to Launch GARDian(TM), a Groundbreaking Initiative That Helps Provide Continued Access to GAMMAGARD for Current Patients
10. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
11. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4
Breaking Biology News(10 mins):University of Texas Southwestern Medical Center researcher wins Avanti Award in lipids 2Canna can: Ornamental eliminates pollutants from stormwater runoff 2National Foundation for Infectious Diseases 28NFID 29 Survey 3A Parents More Flu Aware and More Likely to Get Kids Vaccinated 5552 1National Foundation for Infectious Diseases 28NFID 29 Survey 3A Parents More Flu Aware and More Likely to Get Kids Vaccinated 5552 2National Foundation for Infectious Diseases 28NFID 29 Survey 3A Parents More Flu Aware and More Likely to Get Kids Vaccinated 5552 3National Foundation for Infectious Diseases 28NFID 29 Survey 3A Parents More Flu Aware and More Likely to Get Kids Vaccinated 5552 4PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 1PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 2PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 3PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 4PhRMA Statement Supporting Fair Incentives for Biologics Innovation 5550 5Genedata and the Institute of Experimental Medicine Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 14522 1Genedata and the Institute of Experimental Medicine Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 14522 2Genedata and the Institute of Experimental Medicine Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 14522 3Genedata and the Institute of Experimental Medicine Academy of Sciences of the Czech Republic Collaborate on Asthma Bronchiale Project 14522 4